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Single nucleotide polymorphisms (SNPs) in DNA glycosylase genes
involved in the base excision repair (BER) pathway can modify breast and
ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. We previ-
ously found that SNP rs34259 in the uracil-DNA glycosylase gene (UNG)
might decrease ovarian cancer risk in BRCA2 mutation carriers. In the pre-
sent study, we validated this finding in a larger series of familial breast and
ovarian cancer patients to gain insights into how this UNG variant exerts
its protective effect. We found that rs34259 is associated with significant
UNG downregulation and with lower levels of DNA damage at telomeres.
In addition, we found that this SNP is associated with significantly lower
oxidative stress susceptibility and lower uracil accumulation at telomeres in
BRCA2 mutation carriers. Our findings help to explain the association of
this variant with a lower cancer risk in BRCA2 mutation carriers and high-
light the importance of genetic changes in BER pathway genes as modifiers
of cancer susceptibility for BRCA1 and BRCA2 mutation carriers.
1. Introduction
Women carrying germline mutations in the BRCA1 and
BRCA2 genes have a high lifetime risk of developing
breast, ovarian, and other cancers (Milne et al., 2008).
However, mutation carriers show considerable differ-
ences in disease manifestation, and this suggests the
existence of other genetic or environmental factors that
modify the risk of cancer development. BRCA proteins
are involved in double-strand break (DSB) DNA repair
through the homologous recombination pathway
(O’Donovan and Livingston, 2010), and cells harboring
mutations in these genes are dependent on other DNA
repair mechanisms. In this regard, we have shown that
single nucleotide polymorphisms (SNPs) in genes from
the base excision repair (BER) pathway can modify
breast or ovarian cancer susceptibility in BRCA1 and
BRCA2 mutation carriers (Osorio et al., 2014).
The BER pathway corrects base lesions that result
from deamination, oxidation, or methylation (Xue
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et al., 2016). BER is initiated by DNA glycosylases that
cleave the N-glycosylic bond between the sugar and the
base, and release the damaged base to form an abasic
site, also termed an apurinic/apyrimidinic (AP) site
(Maynard et al., 2009). A deficiency in BER can give
rise to an accumulation of DSBs, which in the presence
of a defective BRCA1 or BRCA2 background can per-
sist and lead to cell cycle arrest or cell death. A syn-
thetic lethal interaction was described between the
BRCA1/2 genes and poly(ADP-ribose) polymerase
(PARP1) involved in the BER pathway, with BRCA-
deficient cells being extremely sensitive to PARP1 inhi-
bitors (Bryant et al., 2005; Farmer et al., 2005).
On the other hand, the BER pathway is essential for
maintaining telomere integrity in mammals (Jia et al.,
2015). Telomeres are susceptible to uracil misincorpo-
ration, which is primarily recognized and removed by
the uracil-DNA glycosylase (UNG) (Cortizas et al.,
2016). Due to the presence of long arrays of
TTAGGG repeats, uracil can appear in telomeric
DNA by misincorporation of deoxyuridine triphos-
phate (dUTP) instead of deoxythymidine triphosphate
(dTTP) opposite adenine or by deamination of cyto-
sine to uracil opposite guanine (Krokan et al., 2002).
Accumulation of uracil interferes with telomere home-
ostasis, and UNG-initiated BER is necessary for the
preservation of telomere integrity (Vallabhaneni et al.,
2015).
In view of the above, we hypothesized that SNPs in
DNA glycosylase genes might interfere with telomere
maintenance and thus contribute to the risk of devel-
oping cancer. Supporting this idea, we reported that
variant rs2304277, located in the 30-UTR of the glyco-
sylase gene OGG1, is associated with higher ovarian
cancer risk in BRCA1 mutation carriers, probably due
to transcriptional downregulation of OGG1 and
increased DNA damage and telomere instability
(Benıtez-Buelga et al., 2016). Similarly, we analyzed
variant rs804271, previously associated with increased
breast cancer risk in BRCA2 mutation carriers (Osorio
et al., 2014), which is located within the promoter
region of the glycosylase gene NEIL2. The modifier
effect of this variant may be due to its negative impact
on the performance of the NEIL2 enzyme, leading to
an accumulation of oxidative lesions at telomeres
(Benıtez-Buelga et al., 2017).
In the present study, we aimed to explain the molec-
ular basis of the protective effect exerted by a SNP
located in the 30-UTR of the UNG gene (rs34259) in
BRCA2 mutation carriers (Osorio et al., 2014). For
that purpose, we explored the effects of the SNP on
UNG activity and expression levels, and its possible
involvement in telomere integrity.
2. Materials and methods
2.1. Patients and healthy controls
The study was performed in accordance with the princi-
ples of the Declaration of Helsinki. All patients and
controls signed an appropriate informed consent form,
and the proposal was approved by the ethics committee
at the Fuenlabrada University Hospital, Madrid, Spain.
We studied a familial breast and ovarian cancer
(FBOC) series of 344 individuals from 173 families
meeting high-risk criteria, and screened for deleterious
mutations in the BRCA1 and BRCA2 genes, as
reported previously (Milne et al., 2008). Thirty-two
families carried a deleterious mutation in BRCA1, 31
in BRCA2, and 110 did not carry any mutation in
either of these two genes (BRCAX families). One hun-
dred eleven controls were included who were relatives
of BRCA1/2 mutation carriers, did not have personal
cancer antecedents, and did not harbor the corre-
sponding familial mutation in the BRCA1 or BRCA2
genes. The different traits studied in this series are
detailed in Table 1.
2.2. DNA extraction and genotyping of SNP
rs34259
DNA was extracted from peripheral blood of FBOC
patients using the Maxwell FSC Instrument
Table 1. Characteristics of the FBOC series and the number of
persons studied for the indicated traits.
BRCA1 BRCA2 BRCAXa Controlsb
Total
(FBOC)
Families 32 31 110 – 173
Healthy carriers 25 34 – – 59
Cancer cases 26 28 120 – 174
SNP rs34259
genotyping
51 63 120 110 344
UNG mRNA
expression
37 53 104 83 277
UNG protein
expression
– 20 – 10 30
Uracil at
telomeres
42 63 115 108 328
Telomere
oxidation
23 19 68 62 172
Protein
carbonylation
29 27 31 20 107
Telomere length 36 32 85 61 214
Telomerase
activity
13 15 – 47 75
a Non-BRCA1/2 families. b Controls were relatives without cancer
antecedents and negative for BRCA1/2 mutations.
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(Promega, Madison, WI, USA) following the manufac-
turer’s instructions and quantified by the PicoGreen
fluorometric assay (Thermo Fisher Scientific, Wal-
tham, MA, USA).
Single nucleotide polymorphism genotyping was car-
ried out using a KASPar probe specifically designed
for rs34259 (LGC Genomics, Berlin, Germany). Allelic
discrimination assays were performed in duplicate
using the 7900HT Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) and the
Abi QuantStudio 6 Flex Real-Time PCR System
(Applied Biosystems) following the instrument-specific
conditions detailed by the manufacturer (LGC Geno-
mics).
2.3. RNA expression analysis
RNA was extracted from peripheral blood mononu-
clear cells using TRIzol Reagent (Thermo Fisher Sci-
entific). RNA quantity and quality were assessed by
NanoDrop (ND-1000 V3.7.1; Thermo Fisher Scien-
tific). The High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems) was utilized for cDNA syn-
thesis following the manufacturer’s instructions.
The human UNG gene encodes both nuclear
(UNG2) and mitochondrial (UNG1) forms of uracil-
DNA glycosylase (Nilsen et al., 1997). We designed
specific primers to quantify total UNG mRNA expres-
sion and the relative expression of each isoform. Two
microliters of cDNA at a final concentration of
10 nglL1 was mixed with GoTaq qPCR MasterMix
19 (Promega) and 1 lM cDNA primers of each pair of
primers (F/R) in a final volume reaction of 10 lL. Pri-
mers used are listed in Table S1. The amplification con-
ditions consisted of an initial step at 95 °C for 10 min,
followed by 40 cycles of 10 s at 95 °C and 1 min at
65 °C. Each qPCR was performed in triplicate includ-
ing no-template controls in an Abi QuantStudio 6 Flex
Real-Time PCR System (Applied Biosystems). Relative
UNG/UNG1/UNG2 mRNA expression was calculated
using the 2DDCt method for qPCR analysis after nor-
malization with the housekeeping gene GAPDH using
the QUANTSTUDIOTM Real-Time PCR Software (Applied
Biosystems).
2.4. Western blotting
The expression of UNG1 was quantified by western
blot analysis in a subset of controls (n = 10) and
BRCA2 mutation carriers (n = 20) from the FBOC ser-
ies. Briefly, peripheral blood mononuclear cells were
isolated from whole blood using TRIzol Reagent
(Thermo Fisher Scientific) according to manufacturer’s
instructions. Cell lysates were prepared in RIPA buffer
(Sigma-Aldrich, San Luis, MO, USA) in the presence
of a protease inhibitor cocktail (Roche, Basel, Switzer-
land). Total protein concentration was determined
using the Pierce BCA Protein Assay Kit (Thermo
Fisher Scientific) following the manufacturer’s instruc-
tions. Sixty micrograms of protein was analyzed by
SDS/PAGE and transferred to Immobilon-FL mem-
branes (Millipore, Burlington, MA, USA). Membranes
were blocked in TBS-T (50 mM Tris/HCl, 150 mM
NaCl, pH 7.5 plus 0.2% Tween-20) and 5% nonfat
milk for 1 h at RT. Blots were probed with the follow-
ing primary antibodies: mouse anti-UNG (#TA503563;
OriGene, Rockville, MD, USA) at 1/1000 dilution and
mouse anti-actin (A2228; Sigma-Aldrich) at 1/10 000
dilution in TBS-T containing 5% nonfat milk. Anti-
mouse IgG-HRP (Dako, Glostrup, Denmark) was
used as the secondary antibody, and the immunoblots
were developed using Immobilon Classico Western
HRP substrate (Millipore). Each western blot was per-
formed in quadruplicate. Images were analyzed using
IMAGEJ software (NIH Image, Bethesda, MD, USA),
and UNG1 protein level was normalized by actin.
In parallel, given that UNG2 protein levels in
peripheral blood mononuclear cells from the FBOC
series were too low to analyze their relative expression,
we also performed western blot analyses of a previ-
ously described set of 18 lymphoblastoid cell lines
(LCLs) (Vaclova et al., 2015) proceeding from BRCA1
mutation carriers and controls following the same
protocol.
2.5. Measurement of telomere damage
2.5.1. Oxidative DNA damage within telomeres
We used a qPCR-based method previously described
to evaluate the accumulation of oxidative lesions
within telomeric DNA based on differences in PCR
kinetics between template DNA digested by formami-
dopyrimidine-DNA glycosylase (FPG) and undigested
DNA (O’Callaghan et al., 2011). Incubation and
qPCR amplification of genomic DNA were performed
as described by O’Callaghan et al. (2011) to estimate
oxidative DNA damage levels at telomeres and the
36B4 locus.
2.5.2. Quantification of uracil accumulation at telomeres
The telomere oxidation protocol (O’Callaghan et al.,
2011) can be adapted to quantify the accumulation of
different base lesions by incubating the DNA with
other glycosylases that are sensitive to other specific
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base lesions. We used UNG to measure the accumula-
tion of uracil, which is recognized and excised by this
enzyme (Hegde et al., 2008), at telomeres.
Due to the high affinity of UNG for DNA (Zhar-
kov et al., 2010), we optimized the protocol using a
low UNG concentration and decreasing DNA
amounts and incubation times. One hundred and
eighty nanograms of genomic DNA was incubated in
the absence or presence of 130 nM UNG (provided
by T. Helleday, Karolinska Institutet, Stockholm,
Sweden) in reaction buffer (25 mM Tris/HCl pH 8.0,
15 mM NaCl, 2 mM MgCl2, and 0.0025% Tween-20)
for 30 min at 37 °C. The reaction was stopped by
incubation at 95 °C for 5 min. qPCR analysis was
performed on 10 ng of digested or undigested geno-
mic DNA using the same reagents and conditions as
described in the original protocol for FPG
(O’Callaghan et al., 2011).
2.6. Immunodetection of oxidized proteins
Oxidized proteins in plasma samples were detected by
measuring the levels of carbonylated proteins as previ-
ously described (Garcıa-Gimenez et al., 2012). Car-
bonylated proteins are a widely used biomarker of
chronic oxidative stress (Fedorova et al., 2013).
2.7. Telomere length measurement
Telomere length (TL) was quantified by high-through-
put quantitative fluorescence in situ hybridization (HT-
QFISH) with automated fluorescence microscopy as
previously described (Canela et al., 2007). Because TL
is strongly heritable (Pooley et al., 2013), BRCA sta-
tus, the presence or absence of the SNP, and TL were
assessed in the same member of each family. Whenever
possible, we used the index case, and if this sample
was not available, we used the most recently geno-
typed individual. As we previously demonstrated that
chemotherapy affects TL (Benıtez-Buelga et al., 2015),
we excluded patients from the analysis who were
undergoing this treatment.
2.8. Telomerase assay
Protein extracts were obtained from peripheral blood
mononuclear cells cultured in RPMI supplemented
with 20% fetal bovine serum and phytohemagglutinin
during 4–5 days, according to the recommendations of
the manufacturer of the TRAPeze telomerase detection
kit (Millipore). The average telomerase activity was
determined in each sample using 0.5, 0.25, and
0.125 lg of protein extract and normalized with the
internal control included in the assay. Because telom-
erase activity can be affected by chemotherapeutic
agents (Benıtez-Buelga et al., 2015), we excluded all
patients who received chemotherapy at any time
during their lifetime.
2.9. Statistical analysis
To evaluate the effect of the SNP for each of the stud-
ied variables, we considered heterozygotes and
homozygotes (GC/CC) as a single group, as the cancer
modifier effect of rs34259 acts in a dominant fashion
in BRCA2 mutation carriers (Osorio et al., 2014).
Pearson’s chi-squared test was used to calculate
whether the frequency of the SNP among the FBOC
groups was significantly different from the frequency
reported in the 1000 Genomes Project for the Iberian
subpopulation (Zerbino et al., 2018). The Spearman
correlation test was used to establish whether correla-
tions between variables were statistically significant.
We performed linear regression analysis to test whether
cancer antecedents in BRCA1 and BRCA2 mutation
carriers were associated with any of the variables evalu-
ated in this study, but we did not find significant differ-
ences (P < 0.05) between healthy BRCA1 and BRCA2
carriers or cancer cases. Hence, we did not stratify for
cancer status in these groups (Table S2).
The Kolmogorov–Smirnov test was used to evaluate
whether the data sets were normally distributed. For
comparative analyses, statistically significant differ-
ences were assessed by an unpaired t-test for normal
distributions and the Mann–Whitney U-test for non-
normal distributions. Linear regression analysis includ-
ing the UNG SNP as explanatory variable was run to
test whether this SNP affected the variables studied.
The effect size of the studied variant was defined as
the slope of the linear regression line and was com-
puted as the effect of the alternative allele (C) relative
to the reference allele (G).
Statistical calculations and graphs were done using
the SPSS software package version 19.0 (IBM, Armonk,
NY, USA) and GRAPHPAD PRISM 5.03 (GraphPad Soft-
ware Inc, San Diego, CA, USA). In all analyses, a 2-
tailed P value < 0.05 was considered statistically signif-
icant.
3. Results
3.1. Association study, validation, and fine
mapping
In a previous study, using a tagging SNP approach in
a large series of BRCA1 and BRCA2 mutation carriers
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(n = 23 463) from the CIMBA consortium, we found
that SNP rs34259 showed the strongest association
with ovarian cancer risk among all SNPs covering the
UNG gene (tagged or imputed): HR: 0.80, 95% CI:
0.69–0.94, P = 7.6 9 103 (Osorio et al., 2014). This
association was confirmed in a larger series of BRCA2
mutation carriers (4291 new cases) from the OncoAr-
ray Consortium (Amos et al., 2017) (HR: 0.84,
P = 7.6 9 103).
SNP rs34259 is located in the 30UTR of the UNG
gene, 2.4 kb downstream of the translation termina-
tion codon. Using HAPLOREG v4.1 (Ward and Kellis,
2012), we were not able to detect a more plausible
causal SNP among those in high linkage disequilib-
rium with rs34259 according to their predicted regula-
tory features (Table S3). Indeed, rs34259 has been
identified as a trans expression quantitative trait locus
(eQTL) SNP that decreased UNG gene expression in
two independent eQTL studies (Ardlie et al., 2015;
Westra et al., 2013) and we considered it the best
candidate.
We genotyped SNP rs34259 in the FBOC sample set
to evaluate its association with the studied variables.
Genotype distributions were in Hardy–Weinberg equi-
librium (v2 = 0.03; P = 0.86). The different groups of
cases and controls presented similar genotype and
allele frequencies, not statistically different from the
frequencies reported in the 1000 Genomes Project for
the Iberian subpopulation (Zerbino et al., 2018)
(Table S4).
3.2. rs34259 is associated with lower UNG mRNA
and protein levels
We first analyzed the SNP effect on transcriptional
regulation in different tissues using the GTEx eQTL
web server (Carithers et al., 2015). We found signifi-
cantly decreased UNG mRNA levels associated with
SNP rs34259 in several tissues, including breast (effect
size = 0.17; P = 0.023) and blood (effect
size = 0.19; P < 0.0001; Table S5).
In parallel, we analyzed UNG mRNA levels in the
FBOC series considering the BRCA status and the
presence or absence of the UNG variant (Fig. 1A).
First, we confirmed in a subgroup of samples (n = 97)
that the mRNA levels of both UNG isoforms (UNG1
and UNG2) were highly correlated (r = 0.551;
P < 0.001) and that total UNG mRNA expression was
correlated with each of the two isoforms and, there-
fore, representative of both (Fig. S1). We detected sig-
nificantly lower UNG mRNA expression in individuals
harboring the variant (effect size = 0.209; P < 0.001).
The effect was more pronounced in the BRCA2 group
(effect size = 0.366; P = 0.007) and remained signifi-
cant when analyzing both isoforms separately
(Fig. S2).
Given that the SNP protective effect is for ovarian
cancer, we also determined UNG mRNA expression in
tissues of 17 prophylactic oophorectomies from
BRCA1 and BRCA2 mutation carriers. In this cohort,
we also found a trend toward lower total UNG mRNA
expression associated with the studied SNP (P = 0.056;
Fig. S3), which was significant for the UNG1 isoform
(P = 0.045).
To confirm whether this downregulation was trans-
lated into lower expression of the protein, we deter-
mined UNG1 protein expression by western blotting
(WB) in 10 controls, of which 4 were carriers of the
SNP, and in 20 BRCA2 carriers, of which 10 were
carriers of the SNP (Fig. 1B). Quantification showed
that BRCA2 carriers harboring SNP rs34259 had
lower UNG1 protein levels (P = 0.023) when controls
and BRCA2 carriers were combined, and the effect of
SNP rs34259 on UNG1 protein levels remained sig-
nificant (P = 0.021; Fig. 1C). UNG1 mRNA levels
correlated significantly with UNG protein levels in
these patients (r = 0.791; P < 0.001) (Fig. 1D).
Finally, we performed WB of both UNG1 and
UNG2 in a set of 18 LCLs and confirmed that both
UNG isoforms remained highly correlated at the pro-
tein level (r = 0.829; P < 0.001; Fig. S4A,B). Despite
the reduced sample size, we also found a trend
toward lower UNG1 and UNG2 protein levels in the
LCL series associated with the UNG variant
(Fig. S4C).
3.3. Accumulation of DNA damage at the
telomeres
We analyzed the accumulation of two kinds of lesions:
8-oxoguanine and uracil, which are detected by FPG
and UNG glycosylases, respectively.
3.3.1. SNP rs34259 is associated with lower oxidative
DNA damage
When analyzing the accumulation of 8-oxoguanine, we
observed significantly lower oxidation levels in individ-
uals harboring the variant (P = 0.008) (Fig. 2A). We
were not able to detect significant differences within
each mutational group. However, a statistically signifi-
cant lower oxidative DNA damage associated with the
SNP was found in controls (P = 0.009), suggesting
that the SNP is associated with lower oxidative dam-
age accumulation at telomeres independently of the
BRCA status.
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3.3.2. BRCA2 mutation carriers harboring SNP rs34259
show lower uracil accumulation at the telomeres
After treatment with UNG, telomeric DNA showed
an average decrease of 54% in PCR amplification
compared to a 22% decrease observed when amplify-
ing the 36B4 control locus (P < 0.0001), reflecting a
predominant presence of uracil in telomeres (Fig. S5).
We did not find significant differences in uracil levels
at telomeres among BRCA groups or controls. How-
ever, when we stratified according to the SNP (Fig. 2B),
we detected a significantly lower uracil accumulation at
telomeres when the variant was present for BRCA2
mutation carriers (P = 0.01). This result suggests that
the protective effect for ovarian cancer risk associated
with SNP rs34259 in BRCA2 mutation carriers could
be due to an increased UNG activity, leading to less
accumulation of uracil at the telomere region.
3.4. Lower protein carbonylation level in
individuals harboring SNP rs34259
No significant differences were found in carbonylation
levels in relation to the BRCA status. Notwithstand-
ing, we found a trend toward lower carbonylation
levels in all FBOC individuals with the variant
(P = 0.052). In addition, for BRCA2 mutation carriers
harboring the SNP we detected a significantly lower
carbonylation level (P = 0.016) (Fig. 3). These results
suggest that the SNP in UNG is associated with lower
oxidative stress susceptibility that becomes pronounced
in BRCA2 mutation carriers.
Fig. 1. UNG mRNA and protein levels. (A) UNG mRNA levels in the various FBOC groups according to the presence or absence of the SNP
[noncarriers (GG)/carriers (GC/CC)]. (B) UNG1 protein levels in controls (n = 10) and BRCA2 mutation carriers (n = 20) according to the
presence or absence of the SNP [noncarriers (GG)/carriers (GC/CC)]. Actin levels were used to normalize for protein loading. (C)
Quantification of UNG1 protein levels of the western blot shown in (B). Bars show the mean and the standard error of the mean (SEM).
Numbers in brackets indicate sample size. (D) Correlation analysis between UNG1 mRNA and protein levels in the patients shown in (B).
Unpaired t-tests were performed for statistical significance in (A) and (C), Spearman’s test was used to test the significance of the
correlation in panel (D).
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3.5. Shorter telomeres in BRCA2 mutation
carriers harboring the SNP
We first evaluated TL distribution in 91 healthy
women as a function of age to obtain a regression line
to adjust TL in the FBOC samples. As expected, we
found a decrease in TL with age (Fig. S6). When the
effect of rs34259 was analyzed for each BRCA muta-
tion group, we only found a significant effect among
BRCA2 mutation carriers: In this group, SNP carriers
had a reduced age-adjusted TL (P = 0.018; Fig. 4A)
and showed a trend toward accumulation of short
telomeres (P = 0.067; Fig. 4B).
3.6. Telomerase activity
We found a significant correlation between telomerase
activity and telomere length (r = 0.313; P < 0.001).
Mean telomerase activity was lower when the SNP
was present in all groups, but it did not reach statisti-
cal significance (Fig. S7).
4. Discussion
The SNP rs34259 in the 30UTR of the UNG gene may
decrease ovarian cancer risk in BRCA2 mutation carri-
ers (Osorio et al., 2014). However, the molecular
mechanism underlying this association is unknown. In
the present report, we show that rs34259 is associated
with significant UNG downregulation and with lower
levels of oxidative DNA damage at telomeres. In addi-
tion, we found that for BRCA2 mutation carriers the
SNP is associated with significantly lower oxidative
stress susceptibility and lower uracil accumulation at
telomeres.
As it has been previously demonstrated that the
region where the variant is located is a potential seed
A B
Fig. 2. Telomere DNA damage in the various FBOC groups according to the presence or absence of the UNG SNP. (A) DNA oxidation at
telomeres. (B) Detection of uracil at telomeres in FBOC patients. Bars show the mean and the SEM. Numbers in brackets indicate sample
size. Mann–Whitney U-test was used in (A), unpaired t-test was used in (B).
Fig. 3. Immunodetection of protein-bound carbonyl groups in
plasma samples from the FBOC series. Carbonylation levels in the
different groups stratified according to the presence or absence of
SNP rs34259 in UNG [noncarriers (GG)/carriers (GC/CC)]. Bars
show the mean and the SEM. Numbers in brackets indicate
sample size. Unpaired t-tests were performed for statistical
significance. A.U., arbitrary units.
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site for microRNAs that downregulate UNG expres-
sion (Hegre et al., 2013), we decided to explore the
effect of this SNP on UNG mRNA and protein levels.
We detected significantly lower UNG mRNA and
UNG1 protein levels associated with SNP rs34259,
which became pronounced in BRCA2 mutation carri-
ers. It has been shown that overexpression of human
UNG in yeast causes DNA damage due to the genera-
tion of AP sites faster than they are repaired (Elder
et al., 2003). In this regard, the lower UNG expression
associated with rs34259 may prevent AP repair from
becoming saturated, and this may in part explain its
protective effect.
Given the dominant role of UNG for processing
uracil at telomeres (Cortizas et al., 2016), we evaluated
uracil accumulation and observed that this was higher
in telomeric DNA than in other genomic regions
(Fig. S5), confirming that telomeres are prone to uracil
accumulation (Vallabhaneni et al., 2015). When we
analyzed the SNP effect, we found significantly lower
uracil accumulation when the SNP was present, but
only for BRCA2 carriers (Fig. 2B). This suggests that
rs34259 could have a positive impact on UNG enzyme
performance that may help to explain the protective
effect of this SNP in BRCA2 carriers.
Furthermore, we explored the impact of this SNP
on other features related to telomere biology, such as
oxidative damage. Because telomeres are especially
susceptible to DNA oxidation (O’Callaghan et al.,
2011; Von Zglinicki et al., 2000), we evaluated the
accumulation of 8-oxoguanine as a measure of oxida-
tive damage. We observed significantly lower 8-oxo-
guanine levels in individuals harboring the variant
(Fig. 2A), suggesting that the SNP is associated with
lower oxidative DNA damage accumulation at the
telomeres.
We found that the SNP impact on UNG expression
affects both nuclear (UNG2) and mitochondrial
(UNG1) isoforms (Fig. S2). Therefore, apart from the
telomeres, it is probable that mitochondrial DNA of
patients harboring the SNP presents lower damage,
given that oxidative base lesions in mitochondria are
repaired by UNG1 (Akbari et al., 2007). In addition,
we analyzed whether the lower levels of oxidative
DNA damage associated with the SNP could be
related to lower chronic oxidative stress susceptibility.
We found lower protein carbonylation levels when
rs34259 was present (Fig. 3), and this was more pro-
nounced in BRCA2 mutation carriers. These results
suggest that the SNP in UNG is associated with lower
oxidative stress susceptibility, especially for BRCA2
carriers. Oxidative stress plays an important role in the
development and progression of cancer (Valko et al.,
2006), and therefore, the lower oxidative stress
A B
Fig. 4. Telomere length and percentage of short telomeres. (A) Distribution of telomere length (kb) values adjusted for age in the FBOC
series according to the presence or absence of the UNG SNP [noncarriers (GG)/carriers (GC/CC)]. (B) Comparative analysis of FBOC groups
regarding the percentage of short (< 3 kb) telomeres. Bars show the mean and the SEM. Numbers in brackets indicate sample size.
Unpaired t-tests were performed for statistical significance.
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associated with the SNP may help to explain the lower
cancer risk of BRCA2 carriers that harbor the SNP.
We also found a significantly shorter TL associated
with the SNP in carriers of BRCA2 mutations
(Fig. 4A). TL is regulated by the shelterin protein
complex that protects telomeres (De Lange, 2005) and
by telomerase, a ribonucleoprotein complex that adds
TTAGGG repeats to the chromosome ends (Black-
burn, 2001). Our data reflect this expected positive cor-
relation between TL and telomerase activity. The
accumulation of uracil in telomeres weakens the bind-
ing affinity of the shelterin component POT1, increas-
ing the accessibility of telomerase. Thus, UNG
deficiency causes defective uracil removal that can lead
to lengthening of telomeres, as has been demonstrated
in mice (Vallabhaneni et al., 2015). According to this
model, the short telomeres phenotype observed in
BRCA2 carriers harboring the SNP could be due to
the lower uracil accumulation at telomeres, also associ-
ated with this group, which facilitates shelterin
binding.
5. Conclusions
We have found that the ovarian cancer risk modifier
SNP rs34259 may have a positive impact on UNG
enzyme performance and is associated with lower
oxidative levels in BRCA2 carriers, which may explain
the cancer-protective effect attributed to this SNP in
this group. Taken together, our findings support the
importance of genetic changes in BER pathway genes
as modifiers of cancer susceptibility for BRCA1 and
BRCA2 mutation carriers.
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Fig. S1. (A) Correlation analysis between total UNG
mRNA expression and UNG1 mRNA expression. (B)
Correlation analysis between total UNG mRNA
expression and UNG2 mRNA expression. (C) Correla-
tion analysis between UNG1 mRNA and UNG2
mRNA expression. Spearman’s test was used to assess
the significance of the correlations.
Fig. S2. Expression levels of specific isoforms of UNG
mRNA according to the presence or absence of the
SNP (noncarriers (GG)/carriers (GC/CC)).
Fig. S3. Expression levels of specific isoforms of UNG
mRNA according to the presence or absence of the
SNP (noncarriers (GG)/carriers (GC/CC)) in ovarian
tissue from BRCA1 and BRCA2 patients (n = 17).
Fig. S4. (A) Western blot of UNG1 and UNG2 in a
panel of 18 established lymphoblastoid cell lines
(LCLs) (Vaclova et al., 2015). Briefly, the LCLs were
established by Epstein-Barr virus transformation of
peripheral blood lymphocytes from eleven healthy
women carrying heterozygous mutations in BRCA1
and seven noncarrier relatives (controls). None of the
women included in the study had personal antecedents
of cancer. Cells were cultured in RPMI-1640 media
(Sigma-Aldrich) supplemented with 20% non-heat-
inactivated fetal bovine serum (Sigma-Aldrich), peni-
cillin-streptomycin (Gibco) and Fungizone (Gibco).
Cells were cultured at 37 °C in a 5% CO2 atmosphere
and were maintained in exponential growth by daily
dilution to 106 cellsmL1 complete media. Protein
extraction and western blotting were performed as
described in the Materials and Methods section. (B)
Correlation analysis between UNG1 and UNG2 pro-
tein expression levels in LCLs. Spearman’s test was
used to assess the significance of the correlation. (C)
UNG1 and UNG2 expression levels in the LCL series
according to the presence or absence of the SNP (non-
carriers (GG)/carriers (GC/CC)). Bars show the mean
and the standard error of the mean (SEM). Numbers
in brackets indicate sample size. Unpaired t-tests were
performed for statistical significance. DNA extraction
and SNP genotyping were performed as are described
in the Materials and Methods section.
Fig. S5. PCR amplification efficiency at the untreated
and UNG-treated telomeric and 36B4 loci.
Fig. S6. Telomere length (TL) distribution in periph-
eral blood leukocytes as a function of age for the con-
trol population (n = 91), measured by HT QFISH.
Fig. S7. Comparative analysis of telomerase activity in
the FBOC series according to the presence or absence
of the UNG SNP (noncarriers (GG)/carriers (GC/
CC)).
Table S1. Primers used for UNG RNA expression
analysis.
Table S2. Linear regression analysis in BRCA 1/2
mutation carriers.
Table S3. Variants within the block of linkage disequi-
librium (LD) > 0.8 with SNP rs34259.
Table S4. Frequency distribution of the UNG variant
rs34259 among FBOC groups.
Table S5. Summary of information in the GTEx eQTL
server regarding transcriptional downregulation of
UNG in 16 different tissues when rs34259 is present.
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